Culture Biosciences Adds Life Sciences Veteran to Board

Mike Stapleton joins the board as the company scales its hardware and software platforms.

Apr. 14, 2026 at 1:54pm by

Got story updates? Submit your updates here. ›

A photorealistic studio still-life image of a sleek, metallic biotech instrument with clean geometric shapes, polished surfaces, and dramatic studio lighting on a solid gray background, conceptually representing Culture Biosciences' technology platform.A premium biotech instrument symbolizes Culture Biosciences' focus on commercializing its integrated hardware and software platform.San Francisco Today

Culture Biosciences, a leader in cloud-connected bioprocess development technologies, has appointed Mike Stapleton to its Board of Directors. Stapleton brings decades of experience in life science instruments, software commercialization, and biopharma, which aligns with Culture's strategic priorities as it scales its Stratyx hardware platform and Console SaaS offering. The board transition also includes the departure of co-founder Will Patrick and the completion of a two-year term for Independent Director Beth Webb, who will now serve as a Strategic Advisor.

Why it matters

This board evolution positions Culture Biosciences with the precise expertise needed to commercialize its hardware platform and rapidly scale its AI capabilities through the Console SaaS offering. Stapleton's deep experience in taking life science instruments and software to market globally will be invaluable as the company enters its next phase of growth.

The details

Mike Stapleton is the Chief Business Officer at QbDVision and has over 30 years of experience in the life sciences industry, spanning software, instruments, consumables, services, and pharmaceuticals. He has held senior executive roles at companies like Merck, PerkinElmer, Life Technologies, Accelrys, and Accenture, giving him expertise in digital transformation, life science software commercialization, and building scalable platforms at the intersection of data and biology.

  • Culture Biosciences announced the board changes on April 14, 2026.
  • Stapleton's appointment comes after the company's Series C financing in the fall.

The players

Mike Stapleton

Chief Business Officer at QbDVision and a life sciences leader with more than 30 years of experience spanning software, instruments, consumables, services, and pharmaceuticals.

Will Patrick

Co-founder of Culture Biosciences, who is stepping down from the board as part of the transition.

Beth Webb

An Independent Director at Culture Biosciences, who is completing a two-year board term and will transition to being a Strategic Advisor to the company.

Chris Williams

CEO of Culture Biosciences.

Culture Biosciences

A leader in cloud-connected bioprocess development technologies, based in San Francisco, California.

Got photos? Submit your photos here. ›

What they’re saying

“This Board evolution positions Culture Biosciences with the precise expertise we need as we commercialize our hardware platform and rapidly scale our AI capabilities through our Console SaaS offering.”

— Chris Williams, CEO of Culture Biosciences

“Culture Biosciences has built something genuinely differentiated — a tightly integrated hardware and software platform that addresses unmet needs in bioprocess development. I'm excited to help the team capitalize on that foundation and bring these tools to a wider market.”

— Mike Stapleton, Chief Business Officer at QbDVision

What’s next

The company will continue to commercialize its Stratyx hardware platform and rapidly scale its AI capabilities through the Console SaaS offering, with Stapleton's expertise guiding the way.

The takeaway

Culture Biosciences is positioning itself for the next phase of growth by adding an experienced life sciences executive to its board. Stapleton's background in commercializing instruments and software will be crucial as the company seeks to bring its integrated hardware and software platform to a wider market.